A gastrectomy is an operation to remove part or all of the stomach. It is most commonly performed to treat gastric (stomach) cancer, for which complete (R0, margin-negative) surgical resection is the only potentially curative therapy (Van Cutsem et al., Lancet, 2016; Li et al., JAMA Surgery, 2022). It may also be indicated for other gastric conditions, including large or bleeding gastric tumors, gastrointestinal stromal tumors, refractory peptic ulcer disease, and — in people with a hereditary diffuse gastric cancer (CDH1) mutation — as a risk-reducing (prophylactic) total gastrectomy (Decourtye-Espiard & Guilford, Gastroenterology, 2023). This is a distinct operation from the sleeve gastrectomy performed for weight loss.

The type and extent of gastrectomy are individualized to the tumor's location, size, and stage (Smyth et al., Lancet, 2020). Early, superficial tumors confined to the inner lining may sometimes be removed endoscopically (EMR/ESD) in experienced centers, preserving the stomach; most invasive cancers require formal resection (NCCN Gastric Cancer Guidelines, 2026). Distal or subtotal gastrectomy (removal of the lower two-thirds of the stomach) is used for cancers of the lower stomach, while total gastrectomy (removal of the entire stomach) is used for cancers of the upper stomach, diffuse/signet-ring (linitis plastica) tumors, or when an adequate margin cannot otherwise be achieved (Van Cutsem et al., Lancet, 2016; Li et al., JAMA Surgery, 2022). In all cases the regional lymph nodes are removed (lymphadenectomy), with a goal of examining at least 16 nodes for accurate staging (NCCN Gastric Cancer Guidelines, 2026). Because gastric cancer is usually treated with chemotherapy (and, for some tumors, immunotherapy) before and/or after surgery, care is coordinated by a multidisciplinary team (Patel et al., JAMA, 2026).

‍

The goal of a cancer gastrectomy is twofold: to remove all visible and microscopic disease (a complete R0 resection with tumor-free margins) and to remove the regional lymph nodes through which stomach cancer characteristically spreads (Li et al., JAMA Surgery, 2022). Because the stomach's lymphatic drainage follows the named arteries of the upper abdomen, an adequate lymphadenectomy — typically a D2 dissection (perigastric nodes plus the nodes along the left gastric, common hepatic, celiac, and splenic arteries) — both improves staging accuracy and, in experienced high-volume hands, lowers locoregional recurrence and cancer-specific mortality (NCCN Gastric Cancer Guidelines, 2026; Li et al., JAMA Surgery, 2022).

Removing part or all of the stomach interrupts the normal path of food, so the surgeon then reconstructs the digestive tract to restore continuity. After a distal/subtotal gastrectomy, the gastric remnant is joined to the duodenum (Billroth I) or to a loop of jejunum (Billroth II), or reconstructed as a Roux-en-Y; after a total gastrectomy, the esophagus is joined directly to the small intestine as a Roux-en-Y esophagojejunostomy (Nishizaki et al., Cochrane Database of Systematic Reviews, 2021; Van Cutsem et al., Lancet, 2016). The reconstruction chosen influences later digestive symptoms, which is why it is tailored to the patient (Nishizaki et al., Cochrane Database of Systematic Reviews, 2021).

‍

• The only potentially curative treatment for localized gastric cancer — complete (R0) resection with lymphadenectomy offers the best chance of cure, with 5-year relative survival around 75% for stage I disease (Van Cutsem et al., Lancet, 2016; Patel et al., JAMA, 2026).

• Accurate staging that guides further treatment — examining ≥16 lymph nodes refines the cancer stage and determines whether additional chemotherapy or immunotherapy is needed (NCCN Gastric Cancer Guidelines, 2026).

• Durable survival for long-term survivors — the risk of cancer-related death falls substantially with each year survived after surgery, and patients alive at 5 years have a very high probability of reaching later milestones (Imataki et al., Journal of Gastrointestinal Surgery, 2025).

• Minimally invasive recovery when appropriate — in selected patients, laparoscopic and robotic gastrectomy achieve oncologic outcomes comparable to open surgery with less pain, fewer wound complications, and shorter hospital stay (Li et al., JAMA Surgery, 2022; Smyth et al., Lancet, 2020).

• Relief of tumor-related symptoms — resection addresses bleeding, obstruction, and pain caused by the tumor (NCCN Gastric Cancer Guidelines, 2026).

• Prevention of a near-certain cancer — for people with a CDH1 mutation, risk-reducing total gastrectomy removes the lifetime risk of diffuse gastric cancer (Decourtye-Espiard & Guilford, Gastroenterology, 2023).

‍

The ideal candidate has localized or locally advanced gastric cancer that is potentially resectable, with no distant metastases, and is medically fit to tolerate major surgery (NCCN Gastric Cancer Guidelines, 2026). Candidacy is determined by a multidisciplinary team after complete staging. Favorable features include:

• Localized disease (cM0) — tumor confined to the stomach ± regional lymph nodes on CT of the chest/abdomen/pelvis, endoscopic ultrasound, and (when indicated) PET/CT and staging laparoscopy (Patel et al., JAMA, 2026).

• T1b or deeper invasive cancer — surgery is primary therapy for invasive tumors, actively bleeding cancer, or when postoperative therapy is planned (NCCN Gastric Cancer Guidelines, 2026).

• Adequate performance status and organ function to tolerate gastrectomy and planned perioperative chemotherapy (Patel et al., JAMA, 2026).

• Very early, superficial tumors (Tis/T1a) meeting criteria may instead be candidates for stomach-sparing endoscopic resection (EMR/ESD) in experienced centers (NCCN Gastric Cancer Guidelines, 2026).

Minimally invasive approaches are appropriate for many clinically operable tumors but are used with caution for bulky T4b or N2 disease (NCCN Gastric Cancer Guidelines, 2026). Patients with distant metastatic disease are generally treated with systemic therapy rather than gastrectomy, with surgery reserved for palliation of bleeding or obstruction (NCCN Gastric Cancer Guidelines, 2026).

‍

Gastrectomy is performed under general anesthesia, either open or — increasingly, when oncologically appropriate — laparoscopically or robotically (Li et al., JAMA Surgery, 2022). The extent of resection is chosen by tumor location: a distal/subtotal gastrectomy removes the lower portion of the stomach for antral and lower-body tumors, while a total gastrectomy removes the entire stomach for proximal, diffuse, or signet-ring tumors, or whenever an adequate margin otherwise cannot be obtained (Smyth et al., Lancet, 2020; Li et al., JAMA Surgery, 2022). The Japanese Gastric Cancer Association recommends gross margins of at least 3 cm for T1–T2 tumors and at least 5 cm for T3–T4 tumors to maximize the chance of an R0 resection (Li et al., JAMA Surgery, 2022).

The surgeon mobilizes the stomach, divides its blood supply, and performs a D2 lymphadenectomy, removing the perigastric nodes and the nodes along the celiac axis and its branches; routine splenectomy is avoided unless the spleen or splenic hilum is directly involved (NCCN Gastric Cancer Guidelines, 2026). After the specimen is removed, digestive continuity is reconstructed — most commonly a Billroth I, Billroth II, or Roux-en-Y after distal gastrectomy, and a Roux-en-Y esophagojejunostomy after total gastrectomy (Nishizaki et al., Cochrane Database of Systematic Reviews, 2021; Junfeng et al., Surgical Endoscopy, 2014). Robotic and laparoscopic techniques follow the same oncologic principles, differing mainly in instrumentation; robotic surgery offers enhanced dexterity and 3D visualization at higher cost and longer operative time, with complication rates and node yields broadly comparable to laparoscopy (Li et al., JAMA Surgery, 2022; Kuwabara et al., Surgical Endoscopy, 2024). In selected patients — particularly for total gastrectomy or when postoperative chemoradiation is likely — a feeding jejunostomy tube may be placed to support nutrition during recovery (NCCN Gastric Cancer Guidelines, 2026).

‍

Gastrectomy for cancer is a major operation, and complications — while reduced in high-volume centers — remain significant and are discussed candidly with every patient. In a large European registry, the overall complication rate was about 30%, with in-hospital, 30-day, and 90-day mortality of 3.2%, 3.6%, and 4.5% (Baiocchi et al., Annals of Surgery, 2020). Potential risks include:

• Anastomotic leak — leakage at a surgical connection (~4.6–9.8%); it has the single greatest impact on mortality, escalation of care, and reoperation after gastrectomy (van Hootegem et al., British Journal of Surgery, 2025; Baiocchi et al., Annals of Surgery, 2020).

• Pulmonary and cardiac complications — among the most frequent and most dangerous, strongly contributing to 30-day mortality (van Hootegem et al., British Journal of Surgery, 2025).

• Infection, intra-abdominal abscess or collection, and postoperative bleeding (Baiocchi et al., Annals of Surgery, 2020).

• Anastomotic stricture — narrowing at the join, occurring in roughly 15% of patients in the 1–3 months after surgery and sometimes requiring endoscopic dilation (Decourtye-Espiard & Guilford, Gastroenterology, 2023).

• Long-term postgastrectomy syndromes — dumping syndrome, bile reflux, and nutritional sequelae (detailed under Long-Term Expectations) (Gallanis et al., Journal of Clinical Oncology, 2024).

• General surgical/anesthetic risks — venous thromboembolism, and the possibility of reoperation.

Anastomotic leakage and pulmonary complications are the highest-yield targets for prevention, which is one reason experience and center volume matter (van Hootegem et al., British Journal of Surgery, 2025).

‍

Recovery is guided by an enhanced recovery after surgery (ERAS) pathway, which standardizes care and speeds return of function (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023). Minimally invasive surgery is associated with less postoperative pain and a shorter hospital stay than open surgery (Smyth et al., Lancet, 2020). Early nutrition is a cornerstone: under ERAS guidance, patients undergoing total gastrectomy may be offered drink and food from postoperative day 1, advancing cautiously according to tolerance, with individualized enteral or parenteral support for those who are malnourished or cannot meet about 60% of their needs by day 6 (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023). Early mobilization is encouraged to reduce pulmonary and clot-related complications (Smyth et al., Lancet, 2020). Because eating capacity is reduced, patients transition to small, frequent, protein-rich meals and work closely with a dietitian during the first months (NCCN Gastric Cancer Guidelines, 2026).

Most patients adapt well to life after gastrectomy, but long-term digestive and nutritional changes are common and require lifelong attention, especially after total gastrectomy (NCCN Gastric Cancer Guidelines, 2026). Expected long-term sequelae include dumping syndrome, bile reflux, early satiety and eating dysfunction, lactose intolerance, fat malabsorption, and deficiencies of vitamin B12, iron, calcium, and vitamin D, with a risk of osteopenia/osteoporosis over time (Decourtye-Espiard & Guilford, Gastroenterology, 2023; Gallanis et al., Journal of Clinical Oncology, 2024). Many solid oral medications are absorbed differently and may need to be switched to liquid or chewable forms (Decourtye-Espiard & Guilford, Gastroenterology, 2023). These are managed — not eliminated — by a multidisciplinary team (dietitian, gastroenterologist, pharmacist) and structured supplementation (NCCN Gastric Cancer Guidelines, 2026). Oncologically, prognosis depends on stage: 5-year relative survival is about 75% for stage I, roughly 45% for locally advanced (stage II–III) disease treated with perioperative therapy and surgery, and under 10% for metastatic disease (Patel et al., JAMA, 2026; Walter, JAMA, 2026). Reassuringly, survival prospects improve the longer a patient survives after surgery, and surveillance intensity is tailored accordingly (I

Gastric surgery outcomes are strongly tied to surgeon and center experience — D2 lymphadenectomy and complex reconstructions achieve the best, safest, most durable results in experienced, high-volume hands, and minimally invasive gastrectomy in particular has a steep learning curve best overcome by dedicated surgeons (Li et al., JAMA Surgery, 2022; Van Cutsem et al., Lancet, 2016). As a board-certified surgeon with advanced expertise in minimally invasive and robotic foregut surgery, Dr. Nestor de la Cruz-Muñoz, MD, FACS, DABOM brings the technical skill required for precise gastric resection, meticulous lymphadenectomy, and tailored reconstruction, and coordinates care within the multidisciplinary oncology team (medical oncology, radiation oncology, gastroenterology, pathology, radiology, and nutrition) that modern gastric cancer treatment demands (Patel et al. , JAMA, 2026; NCCN Gastric Cancer Guidelines, 2026). He emphasizes complete, guideline-concordant staging before surgery, an R0-oriented operative plan with adequate nodal dissection, minimally invasive technique whenever oncologically appropriate to speed recovery, and the structured, lifelong nutritional follow-up that determines long-term quality of life after gastrectomy (NCCN Gastric Cancer Guidelines, 2026; Decourtye-Espiard & Guilford, Gastroenterology, 2023).

‍

Unlike a weight-loss operation, a cancer gastrectomy is not intended to reduce weight — but significant weight loss is an expected consequence of removing part or all of the stomach, and recovery of a healthy weight is a central goal (Smyth et al., Lancet, 2020). After total gastrectomy, weight loss typically peaks at 6–12 months at roughly 20% of baseline body weight, with greater losses in patients who were heavier beforehand (Decourtye-Espiard & Guilford, Gastroenterology, 2023). Preserving a small gastric remnant (as in subtotal or near-total gastrectomy) is associated with better maintenance of body weight, hemoglobin, albumin, and cholesterol than total gastrectomy (Ko et al., Surgical Endoscopy, 2022). Patients are supported with small, frequent, high-protein meals and dietitian guidance to stabilize weight; ongoing or excessive weight loss should prompt evaluation for a treatable cause such as stricture, dumping, or recurrence (NCCN Gastric Cancer Guidelines, 2026).

‍

Expected Symptom & Oncologic Outcomes

The measurable goals after gastrectomy are complete tumor removal, accurate staging, and control of tumor-related symptoms such as bleeding, obstruction, and pain — not metabolic improvement (NCCN Gastric Cancer Guidelines, 2026). An R0 resection with adequate lymphadenectomy maximizes the chance of cure and defines the need for further therapy (Li et al., JAMA Surgery, 2022). Stage-dependent 5-year survival ranges from about 75% (stage I) to roughly 45% (locally advanced with perioperative therapy), and the probability of long-term survival rises with each year survived after surgery (Patel et al., JAMA, 2026; Imataki et al., Journal of Gastrointestinal Surgery, 2025). For appropriately selected early gastric cancer, long-term survival can approach that of the general population (Oh et al., Scientific Reports, 2025).

‍

Removing the stomach and its antireflux mechanism commonly produces bile reflux and dumping syndrome, which are managed proactively (Gallanis et al., Journal of Clinical Oncology, 2024). Bile reflux is the most pervasive postgastrectomy GI symptom and is treated in a stepwise fashion — diet and positional measures (remaining upright after eating, wedge-pillow sleeping) and OTC agents first, prescription medication (e.g., cholestyramine) next, and, for severe refractory cases, surgical revision such as Roux limb lengthening (Gallanis et al., Journal of Clinical Oncology, 2024). Dumping syndrome — early (within 30 minutes: palpitations, diarrhea, nausea, cramps) or late (2–3 hours: dizziness, sweating, faintness) — is managed with frequent small meals high in protein and fiber and low in simple sugars, and by avoiding fluids with meals (NCCN Gastric Cancer Guidelines, 2026). The choice and configuration of reconstruction (e.g., Roux-en-Y vs. Billroth) is made in part to minimize reflux (Nishizaki et al., Cochrane Database of Systematic Reviews, 2021).

‍

Reconstruction and any later revision are individualized to anatomy and symptoms. Primary reconstruction options include Billroth I, Billroth II, or Roux-en-Y after distal gastrectomy, and Roux-en-Y esophagojejunostomy after total gastrectomy, with the choice influencing dumping and reflux (Nishizaki et al., Cochrane Database of Systematic Reviews, 2021; Junfeng et al., Surgical Endoscopy, 2014). For complications or refractory postgastrectomy symptoms, options include endoscopic dilation for anastomotic stricture, conversion or Roux limb lengthening for severe bile reflux, and multidisciplinary management of dumping and nutritional sequelae (Decourtye-Espiard & Guilford, Gastroenterology, 2023; Gallanis et al., Journal of Clinical Oncology, 2024). Pylorus-preserving and proximal gastrectomy with double-tract reconstruction are stomach-function–sparing alternatives for selected early tumors, associated with less dumping and weight loss (Smyth et al., Lancet, 2020).

‍

Many patients enter surgery already depleted by cancer and reduced intake, and gastrectomy accelerates loss of both fat and lean muscle mass, so the postoperative priority is rebuilding — not reducing — body composition (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023). Early enteral nutrition, adequate protein intake, and, when needed, supplemental jejunostomy or parenteral feeding help limit lean-mass loss during the vulnerable early recovery period (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023; NCCN Gastric Cancer Guidelines, 2026). Preserving a gastric remnant where oncologically appropriate supports better long-term weight and nutritional status (Ko et al., Surgical Endoscopy, 2022). A progressive return to physical activity and resistance training, paired with sustained protein intake, helps rebuild the muscle and functional capacity eroded by cancer and surgery.

‍

Gastrectomy for cancer or other gastric disease is covered as a medically necessary treatment for a documented diagnosis, in contrast to elective weight-loss surgery. Payers expect documentation establishing the diagnosis and stage — endoscopic biopsy confirming malignancy (or the relevant pathology), cross-sectional imaging (CT chest/abdomen/pelvis), endoscopic ultrasound, and, where indicated, PET/CT and staging laparoscopy — together with the multidisciplinary treatment plan (Patel et al., JAMA, 2026; NCCN Gastric Cancer Guidelines, 2026). Specific coverage, documentation, coding, and any pre-authorization requirements should be confirmed with each individual plan.

‍

• Complete oncologic staging — upper endoscopy with biopsy, CT of the chest/abdomen/pelvis, endoscopic ultrasound, and PET/CT or staging laparoscopy when indicated (Patel et al., JAMA, 2026).

• Multidisciplinary tumor board review to confirm resectability and plan perioperative chemotherapy/immunotherapy (NCCN Gastric Cancer Guidelines, 2026).

• Nutritional assessment and optimization — malnourished patients are optimized with oral supplements or enteral nutrition before surgery (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023).

• ERAS carbohydrate loading and limited fasting — clear fluids until 2 hours and solids until 6 hours before surgery, with a preoperative carbohydrate drink in patients without diabetes (Rayner & Huddy, Nutritional Management of the Surgical Patient, 2023).

• Standard pre-anesthesia evaluation, smoking cessation, and medical optimization of cardiac and pulmonary risk (van Hootegem et al., British Journal of Surgery, 2025).

‍

Because nutritional deficiency is the central long-term challenge after gastrectomy, prevention is built into lifelong, structured surveillance and supplementation (NCCN Gastric Cancer Guidelines, 2026). Guideline-based measures include: monitoring vitamin B12 at least every 6 months (with B12 supplementation, since intrinsic factor is lost after total gastrectomy); monitoring CBC and iron at least annually with oral or IV iron as needed (avoiding sustained-release or enteric-coated formulations); a daily multivitamin/mineral complex covering vitamins A, C, D, E, folate, thiamine, magnesium, zinc, selenium, and copper; vitamin D and calcium supplementation; and bone-density testing around 3 years post-gastrectomy (and in post-menopausal or older patients) (NCCN Gastric Cancer Guidelines, 2026). Patients with subtotal gastrectomy are at lower risk and can have individualized monitoring (NCCN Gastric Cancer Guidelines, 2026).

‍

Early mobilization and walking are encouraged within the ERAS pathway to reduce pulmonary and clot-related complications (Smyth et al., Lancet, 2020). With minimally invasive surgery there are no large incisions, allowing a quicker return to light activity; open surgery requires a longer, more graduated recovery (Li et al., JAMA Surgery, 2022). Patients progressively resume aerobic activity and, later, resistance training as cleared by the surgical team, with the goal of rebuilding the muscle mass and conditioning lost to cancer and surgery.

‍